Close Menu

NEW YORK (GenomeWeb) – Deutsche Bank has initiated coverage on the life sciences and diagnostics sector, saying it is "generally positive" on the outlook for its fundamentals, even though company valuations are near historical highs, and assigned a Neutral outlook for the group of eight stocks.

Analyst Shawn Bevec assigned Buy ratings to shares of Fluidigm, Myriad Genetics, and Thermo Fisher Scientific, and Hold ratings to shares of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters. He also listed Myriad and Thermo Fisher as "top" picks.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.